If you follow Adam's posts I think an objective person can see he is clearly bullish vertex and anti-Intermune. He backed off a bit on Vertex but I guess he still has something against 191. If you have search capability (I don't) you may want to see one of his past articles criticizing InterMune's 191 program and my reply's to some of his misleading comments.
And one more thing as to Adam's misleading remarks in this article he clearly doesn't read a PR. InterMune additionally reported that, based on a preliminary review of the available and still blinded clinical data from the four completed cohorts of the Phase 1b study, ITMN-191 was safe and well-tolerated. Since Intermune has stated they don't intend to treat HCV patients with 191 only(Pegasys and Copegasys will be part of the treatment regimine) Adam harping about monotherapy is not too real world and is nothing more then a red herring at this point. And his rant about a better then 4.4 well keep in mind the dosing to get that is 5-6x higher then 191 tested doses.
News 
Market Data 
Discover 
AI
